MoneyWorks4Me

Marksans Pharma - Quaterly Results

11 Feb 2022 Evaluate
Revenue showed a marginal decline at Rs. 1659.37 millions. For the quarter ended December 2021, as compared to corresponding quarter of last year.Net profit declined -10.46% to Rs. 260.57 millions from Rs. 291.02 millions.The company reported a degrowth in operating Profit to 398.85 millions from 411.23 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202112 202012 % Var 202112 202012 % Var 202103 202003 % Var
Sales 1659.37 1684.55 -1.49 4820.11 4619.66 4.34 5995.48 4334.15 38.33
Other Income 120.65 62.41 93.32 346.03 192.47 79.78 311.56 1.73 17909.25
PBIDT 398.85 411.23 -3.01 1214.49 1061.79 14.38 1448.68 716.63 102.15
Interest 6.85 10.98 -37.61 25.17 32.07 -21.52 53.45 72.92 -26.70
PBDT 392.00 400.25 -2.06 1189.32 1029.72 15.50 1395.23 643.71 116.75
Depreciation 45.21 40.34 12.07 130.54 110.48 18.16 151.93 116.44 30.48
PBT 346.79 359.91 -3.65 1058.78 919.24 15.18 1243.30 527.27 135.80
TAX 86.22 68.89 25.16 233.18 172.32 35.32 259.49 148.24 75.05
Deferred Tax 1.22 -10.10 -112.08 16.30 -32.97 -149.44 -22.39 36.77 -160.89
PAT 260.57 291.02 -10.46 825.60 746.92 10.53 983.81 379.03 159.56
Equity 409.31 409.31 0.00 409.31 409.31 0.00 409.31 409.31 0.00
PBIDTM(%) 24.04 24.41 -1.54 25.20 22.98 9.62 24.16 16.53 46.14
Peers
Company Name CMP
Sun Pharma. Inds. 1853.50
Dr. Reddys Labs. 1202.80
Cipla 1397.20
Lupin 2090.00
Zydus Lifesciences 1202.00
View more..